Cambium Bio Successfully Closes A$3.0M Financing Round

SYDNEY, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cambium Bio Limited (ASX:CMB) (Cambium Bio, Cambium or Company), a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, is pleased to announce the successful completion of a A$3.0 million capital raising. Key Highlights: Capital raising of A$3.0 million completed at A$0.4637 per share, representing a 25% discount to the 5-day Volume Weighted Average Price (VWAP)